阿尔茨海默氏病研究中心目前的做法是为研究参与者提供报酬
Matthew Gabel1, Semere Bekena2, Mitch O'Meara2
1Department of Political Science, Washington University in St. Louis, St. Louis, Missouri, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|January 27, 2025
概括
大多数阿尔茨海默氏病研究中心 (ADRCs) 提供一些参与者报酬,但实践在很大程度上有所不同. 补偿研究合作伙伴和年度访问是改善帮助阿尔茨海默病 (AD) 研究的招聘和保留的关键领域.
科学领域:
- 神经科学是一个神经科学.
- 临床研究 临床研究
- 公共卫生 公共卫生
背景情况:
- 国家阿尔茨海默病协调中心 (NACC) 的指导建议为所有阿尔茨海默病 (AD) 研究参与者提供报酬.
- 阿尔茨海默病的研究面临着重大的招聘挑战.
- 了解阿尔茨海默氏病研究中心 (ADRCs) 当前的薪酬实践至关重要.
研究的目的:
- 评估ADRC中对纵向研究参与者的现有报酬做法.
- 为了识别赔偿和偿还策略的变化.
- 确定潜在改善参与者报酬的领域.
主要方法:
- 对37个ADRC进行了一项调查,调查了他们对纵向研究参与者的报酬政策.
- 收集的数据包括报酬类型 (补偿与补偿) 和具体的研究程序.
- 实现了100%的响应率,确保了全面的数据.
主要成果:
- 大多数ADRC (32/37) 提供某种形式的报酬.
- 旅行或食物的补偿 (n=29) 和研究程序的补偿 (n=32) 是常见的.
- 然而,大多数中心不报酬研究伙伴 (n=12) 或提供财政激励 (n=8);只有6个ADRC涵盖所有程序.
结论:
- 在ADRC的薪酬实践中存在显著的变化.
- 提高关键领域包括补偿研究伙伴和强制性年度临床/认知评估.
- 需要进一步评估报酬对参与者的招聘和保留的影响,特别是对于代表性不足的群体.
相关概念视频
Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
Ethics in Research
22.9K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
22.9K
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160


